Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	100.3	145.65	123.55	293.83	140.41	96.67
Short-Term Investments	340.25	400.58	516.6	320.97	472.21	339.38
Cash & Short-Term Investments	440.55	546.22	640.15	614.79	612.62	436.05
Cash Growth	-23.44%	-14.67%	4.12%	0.36%	40.49%	-
Prepaid Expenses	9.5	8.46	11.14	11.49	4.93	4.21
Total Current Assets	450.05	554.69	651.3	626.29	617.55	440.26
Property, Plant & Equipment	124.71	142.32	166.27	166.64	124.06	43.71
Long-Term Investments	39.11	48.51	115.04	330.53	163.44	68.98
Other Long-Term Assets	5.35	4.52	4.96	3.95	3.24	2.68
Total Assets	619.22	750.03	937.56	1,127	908.28	555.63
Accounts Payable	3.6	4.82	3.92	3.21	9.4	2.84
Accrued Expenses	21.88	20.36	21.14	22.36	17.84	10.25
Current Portion of Leases	7.13	6.27	4.53	1.17	3.62	0.34
Current Unearned Revenue	-	-	-	4.99	6.1	4.51
Other Current Liabilities	0.91	3.07	7.44	15.01	12.34	4.1
Total Current Liabilities	33.51	34.52	37.03	46.74	49.29	22.05
Long-Term Leases	51.44	56.89	63.17	66.65	50.96	27.13
Long-Term Unearned Revenue	-	-	-	79.67	89.07	98.41
Other Long-Term Liabilities	3.57	3.66	4.11	4.57	0.53	-
Total Liabilities	88.52	95.08	104.31	197.62	189.84	147.58
Common Stock	0.03	0.03	0.03	0.02	0	0
Additional Paid-In Capital	1,683	1,657	1,608	1,516	41.36	18.11
Retained Earnings	-1,153	-1,002	-767.48	-584.36	-334.14	-129.67
Comprehensive Income & Other	0.76	-0.09	-7.6	-1.62	0.26	0.45
Total Common Equity	530.7	654.95	833.25	929.79	-292.53	-111.11
Shareholders' Equity	530.7	654.95	833.25	929.79	718.44	408.06
Total Liabilities & Equity	619.22	750.03	937.56	1,127	908.28	555.63
Total Debt	58.58	63.17	67.7	67.82	54.57	27.47
Net Cash (Debt)	402.08	499.56	642.57	830.51	638.04	443.56
Net Cash Growth	-24.64%	-22.26%	-22.63%	30.17%	43.84%	-
Net Cash Per Share	1.58	1.99	2.60	6.11	48.12	81.70
Filing Date Shares Outstanding	279.22	254.1	249.61	242.79	17.83	5.43
Total Common Shares Outstanding	256.56	253.96	249.57	242.74	15.57	5.43
Working Capital	416.53	520.17	614.27	579.55	568.26	418.21
Book Value Per Share	2.07	2.58	3.34	3.83	-18.79	-20.47
Tangible Book Value	530.7	654.95	833.25	929.79	-292.53	-111.11
Tangible Book Value Per Share	2.07	2.58	3.34	3.83	-18.79	-20.47
Machinery	-	35.85	34.33	29.03	17.99	11.95
Construction In Progress	-	0.13	4.15	10.58	55.71	3.59
Leasehold Improvements	-	118.32	116.93	95	8.45	3.69

Source: S&P Capital IQ. Standard template. Financial Sources.